Munich / Morristown, NJ JUNE 16, 2008 Definiens, the number one Enterprise Image Intelligence company, today announced the introduction of a new multi-dimensional image analysis platform. Software applications built on Definiens XD extract previously unattainable levels of volumetric and morphological intelligence from digital data. They provide scientists and clinicians with a deeper understanding of the subtle biological changes associated with disease progression and treatment, and the action and safety of new therapies.
Definiens XD fulfils formerly unmet needs, including precise and automated volumetric measurements of almost all structures and the ability to analyze virtually any multi-dimensional image data. It is the first image analysis platform to facilitate the automated comparison of images from different modalities, in-vivo and in-vitro data, 2D and 3D images over time, and two-dimensional images to three-dimensional structures in a consistent and reproducible manner. The technology allows consistent and precise 3D volumetric measurement; the most challenging but most accurate way of measuring structures of interest, including various lesions in the human body.
Definiens XD is built upon the next generation of Definiens Cognition Network Technology®, the worlds most advanced technology for extracting intelligence from images. Developed by Gerd Binnig, the 1986 Nobel Laureate for Physics, and his team, the technology emulates human cognitive processes. Definiens technology differentiates itself from pixel-based and model-based matching technologies by recognizing groups of pixels as objects, picking out shapes, colors and textures. The technology examines objects contextually and can understand scale, overlapping objects and the relationship of two-dimensional images to three-dimensional shapes.
Our new Definiens XD platform, enabled by the next generation of Definiens Cognition Network Technology, addresses the growing need for multidimensional image analysis tools in the healthcare industry, said Wolfgang Rencken, Executive Vice President, Technology and Products and Member of the Executive Board of Definiens. Definiens XD expands the capabilities of our technology, allowing us to serve new application fields.
The increasing need for multi-dimensional image analysis technologies is demonstrated by the growth of confocal and fluorescence imaging, kinetic and chemotactic assays and non-invasive imaging. Definiens XD facilitates a wide range of multidimensional image analysis applications:
Basic Research (2D + time series, 3D, 3D + time series)
Advances in fluorescent proteins (GFP, YFP, CFP), a wide range of fluorescent dyes, live cell and fixed cell fluorescence and confocal microscopy has resulted in their rapid adoption by biologists. Obtaining spatial (x, y, z) and time series images for analysis has become a necessity, as has the automated analysis of these images.
Pre-Clinical Small Animal Imaging (3D and 4D)
The growing use of non-invasive imaging devices manufactured for small animal imaging has significantly improved the quality of information derived from research studies. Many images can be acquired at different time points from the same animal and the ability to study the effect of therapeutic interventions in these animal models greatly improves statistical comparisons of therapeutic efficacy. Automating the analysis of this pre-clinical image data is central to the wider adoption of small animal imaging studies which deliver the molecular and preclinical imaging benefits identified in the FDAs 2003 Critical Path to New Medical Products initiative.
Medical Imaging (3D and 4D)
In recent years, a wide range of advanced noninvasive medical imaging techniques have been introduced in biomedical practice, including various combinations of positron emission tomography (PET), dynamic computed tomography (CT), and magnetic resonance imaging (MRI). In addition to the imaging of morphological structure, the analysis and visualization of time series and functional imaging are gaining importance. Automated analysis of this medical imaging data can play a significant role in screening, treatment planning and staging, and computer aided detection (CAD) applications.
The launch of Definiens XD represents an important milestone in the companys expansion in the life sciences market and entrance into the medical imaging market. Over the coming years, Definiens intends to expand its product offerings with CAD applications for medical professionals.
Definiens in Life Sciences
By automating image analysis on an enterprise level, Definiens supports Life Science organizations to analyze and interpret vast numbers of images accurately and consistently. Definiens improves the measurement of cell assays, the examination of tissue samples and the interpretation of non-invasive imaging, enabling high-content screening, digital pathology and translational medicine.
About Definiens
Definiens is the number one Enterprise Image Intelligence company for analyzing and interpreting images on every scale, from microscopic cell structures to satellite images. The Definiens Cognition Network Technology®, developed by Nobel laureate Prof. Gerd Binnig and his team, is an advanced and robust context-based technology designed to fulfill the image analysis requirements of the Life and Earth sciences markets. The technology is modeled on the powerful human cognitive perception processes to extract intelligence from images. Definiens provides organizations with faster image analysis results, allowing deeper insights enabling better business decisions. The company is headquartered in Munich, Germany and has offices throughout the United States. Further information is available at www.definiens.com.
Definiens, Definiens Cellenger, Definiens Cognition Network Technology, Definiens eCognition, Enterprise Image Intelligence and Understanding Images are trademarks or registered trademarks of Definiens.
Press contacts:
Definiens
Rene Hermes, Vice President Marketing
rhermes@definiens.com
Lucy Turpin Communications GmbH
Eva Hildebrandt
definiens@lucyturpin.com
+49 (0)89 417761-14
X